Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
about
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveCan low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.Organ-specific management and supportive care in chronic graft-versus-host disease.Cytomegalovirus in hematopoietic stem cell transplant recipientsOral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer.Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.Management of human cytomegalovirus infection in transplant recipients by the pre-emptive therapy approach
P2860
Q28388806-DA6DBF62-7404-4FF8-BCD8-AAA16982B167Q33410582-8513FFBE-6454-4661-8DC0-988A95BFCB30Q33425731-2C721518-CE8D-4983-AEE6-79462053D81BQ34270868-304B4E4C-24D2-49F8-8714-9B92637F93D5Q35922928-D7357308-57C4-41D4-8499-B77E1D0F510CQ37957308-1D1E83E8-882B-4CD7-B6C4-13243C7DA8C6Q38547042-FE3EC612-6F96-4C72-B032-F91E351E1962Q38617612-C2693688-BA97-48D1-A41C-023013D727A1Q38835171-E7E4AEC7-F505-4FF6-B4B5-50EE789EB14DQ39154605-1D1246CD-7A1D-4D43-BA8D-2D35BEFAFEEEQ41483852-D11B2A7C-95BD-4DCC-B2AC-9BBE05ECDF63Q42022232-0141E6E3-143F-4239-B41D-3106DBBBB521Q44189939-2DD66C97-B5EB-42F2-96F9-B11E5306496BQ48225119-FAD62514-E105-4B16-ADE5-5E90D659B1E8Q57275299-C96DA1CB-9D91-4916-B3D0-A0722A2EA060
P2860
Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Oral valganciclovir as preempt ...... eic stem cell transplantation.
@ast
Oral valganciclovir as preempt ...... eic stem cell transplantation.
@en
type
label
Oral valganciclovir as preempt ...... eic stem cell transplantation.
@ast
Oral valganciclovir as preempt ...... eic stem cell transplantation.
@en
prefLabel
Oral valganciclovir as preempt ...... eic stem cell transplantation.
@ast
Oral valganciclovir as preempt ...... eic stem cell transplantation.
@en
P2093
P2860
P1476
Oral valganciclovir as preempt ...... neic stem cell transplantation
@en
P2093
P2860
P304
P356
10.1111/J.1399-3062.2006.00183.X
P577
2007-06-01T00:00:00Z